$1.41
-0.04[-2.76%]
At close: Apr 26
$1.41
0[0.00%]
PreMarket: 6:31AM EDT
Enlivex Therapeutics
(NASDAQ:ENLV)Enlivex Therapeutics Stock (NASDAQ:ENLV), Analyst Ratings, Price Targets, Predictions
Enlivex Therapeutics Ltd has a consensus price target of $7, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on April 23, 2024, April 12, 2024, and September 25, 2023. With an average price target of $8.67 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 514.66% upside for Enlivex Therapeutics Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Enlivex Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/23/2024 | ENLV | Buy Now | Enlivex Therapeutics | $1.41 | 396.45% | HC Wainwright & Co. | Raghuram Selvaraju | → $7 | Reiterates | Buy → Buy | Get Alert |
| 04/12/2024 | ENLV | Buy Now | Enlivex Therapeutics | $1.41 | 396.45% | HC Wainwright & Co. | Raghuram Selvaraju | $12 → $7 | Maintains | Buy | Get Alert |
| 09/25/2023 | ENLV | Buy Now | Enlivex Therapeutics | $1.41 | 751.06% | HC Wainwright & Co. | Raghuram Selvaraju | $15 → $12 | Maintains | Buy | Get Alert |
| 08/01/2023 | ENLV | Buy Now | Enlivex Therapeutics | $1.41 | 963.83% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/24/2023 | ENLV | Buy Now | Enlivex Therapeutics | $1.41 | 963.83% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | → Buy | Get Alert |
| 04/05/2023 | ENLV | Buy Now | Enlivex Therapeutics | $1.41 | 963.83% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | ENLV | Buy Now | Enlivex Therapeutics | $1.41 | 963.83% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | → Buy | Get Alert |
| 05/02/2022 | ENLV | Buy Now | Enlivex Therapeutics | $1.41 | 963.83% | HC Wainwright & Co. | Raghuram Selvaraju | $33 → $15 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Enlivex Therapeutics (ENLV)?
The latest price target for Enlivex Therapeutics (NASDAQ: ENLV) was reported by HC Wainwright & Co. on April 23, 2024. The analyst firm set a price target for $7.00 expecting ENLV to rise to within 12 months (a possible 396.45% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enlivex Therapeutics (ENLV)?
The latest analyst rating for Enlivex Therapeutics (NASDAQ: ENLV) was provided by HC Wainwright & Co., and Enlivex Therapeutics reiterated their buy rating.
When was the last upgrade for Enlivex Therapeutics (ENLV)?
There is no last upgrade for Enlivex Therapeutics.
When was the last downgrade for Enlivex Therapeutics (ENLV)?
There is no last downgrade for Enlivex Therapeutics.
When is the next analyst rating going to be posted or updated for Enlivex Therapeutics (ENLV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enlivex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enlivex Therapeutics was filed on April 23, 2024 so you should expect the next rating to be made available sometime around April 23, 2025.
Is the Analyst Rating Enlivex Therapeutics (ENLV) correct?
While ratings are subjective and will change, the latest Enlivex Therapeutics (ENLV) rating was a reiterated with a price target of $0.00 to $7.00. The current price Enlivex Therapeutics (ENLV) is trading at is $1.41, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.